{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,7]],"date-time":"2024-07-07T04:41:20Z","timestamp":1720327280419},"reference-count":46,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2012,2]]},"DOI":"10.1016\/j.ijrobp.2010.10.067","type":"journal-article","created":{"date-parts":[[2011,1,28]],"date-time":"2011-01-28T09:29:52Z","timestamp":1296206992000},"page":"817-825","source":"Crossref","is-referenced-by-count":10,"title":["Phase II Study of Concomitant Thalidomide During Radiotherapy for Hepatocellular Carcinoma"],"prefix":"10.1016","volume":"82","clinical-trial-number":[{"clinical-trial-number":"nct00155272","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Hui-Ju","family":"Ch\u2019ang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiun","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chien-Hung","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ya-Hui","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey S.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li-Tzong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2010.10.067_bib1","first-page":"705","article-title":"Hepatocellular carcinoma: One of the world\u2019s most common malignancies","volume":"57","author":"Cook","year":"1985","journal-title":"Q J Med"},{"key":"10.1016\/j.ijrobp.2010.10.067_bib2","first-page":"511","article-title":"Hepatic resection for hepatocellular carcinoma","volume":"107","author":"Tsuzuki","year":"1990","journal-title":"Surgery"},{"key":"10.1016\/j.ijrobp.2010.10.067_bib3","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/BF00316978","article-title":"Nonsurgical treatment of hepatocellular carcinoma in cirrhotic patients","volume":"19","author":"Ohto","year":"1995","journal-title":"World J Surg"},{"key":"10.1016\/j.ijrobp.2010.10.067_bib4","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1002\/1097-0142(19911115)68:10<2150::AID-CNCR2820681011>3.0.CO;2-F","article-title":"Effect of repeated transcatheter arterial embolization on the survival time in patients with hepatocellular carcinoma: An analysis by the Cox proportional hazard model","volume":"68","author":"Ikeda","year":"1991","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2010.10.067_bib5","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1200\/JCO.1993.11.7.1286","article-title":"Treatment of primary hepatobiliary cancers with conformal radiation therapy and regional chemotherapy","volume":"11","author":"Robertson","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2010.10.067_bib6","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/S0360-3016(02)02864-X","article-title":"Dose\u2013response relationship in local radiotherapy for hepatocellular carcinoma","volume":"54","author":"Park","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2010.10.067_bib7","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1046\/j.1440-1746.1999.01994.x","article-title":"A pilot study of three-dimensional conformal radiotherapy in unresectable hepatocellular carcinoma","volume":"14","author":"Cheng","year":"1999","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.ijrobp.2010.10.067_bib8","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S0360-3016(02)03929-9","article-title":"Clinical results and prognostic factors in radiotherapy for unresectable hepatocellular carcinoma: A retrospective study of 158 patients","volume":"55","author":"Seong","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2010.10.067_bib9","first-page":"427","article-title":"Radiotherapy for hepatocellular carcinoma: Clinicopathological study of seven autopsy cases","volume":"41","author":"Aoki","year":"1994","journal-title":"Hepatogastroenterology"},{"key":"10.1016\/j.ijrobp.2010.10.067_bib10","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/ijc.1022","article-title":"Unresectable hepatocellular carcinoma treated with radiotherapy and\/or chemoembolization","volume":"96","author":"Chia-Hsien Cheng","year":"2001","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ijrobp.2010.10.067_bib11","doi-asserted-by":"crossref","first-page":"2706","DOI":"10.1158\/1078-0432.CCR-05-2721","article-title":"Sublethal irradiation induces vascular endothelial growth factor and promotes growth of hepatoma cells: Implications for radiotherapy of hepatocellular carcinoma","volume":"12","author":"Chung","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2010.10.067_bib12","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1002\/hep.510270613","article-title":"Clinical significance of microvessel density and vascular endothelial growth factor expression in hepatocellular carcinoma and surrounding liver: Possible involvement of vascular endothelial growth factor in the angiogenesis of cirrhotic liver","volume":"27","author":"El-Assal","year":"1998","journal-title":"Hepatology"},{"key":"10.1016\/j.ijrobp.2010.10.067_bib13","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1097\/00000658-200102000-00012","article-title":"Serum vascular endothelial growth factor predicts venous invasion in hepatocellular carcinoma: A prospective study","volume":"233","author":"Poon","year":"2001","journal-title":"Ann Surg"},{"key":"10.1016\/j.ijrobp.2010.10.067_bib14","doi-asserted-by":"crossref","first-page":"7009","DOI":"10.1038\/sj.onc.1209706","article-title":"Radiation-enhanced hepatocellular carcinoma cell invasion with MMP-9 expression through PI3K\/Akt\/NF-kappaB signal transduction pathway","volume":"25","author":"Cheng","year":"2006","journal-title":"Oncogene"},{"key":"10.1016\/j.ijrobp.2010.10.067_bib15","doi-asserted-by":"crossref","first-page":"4082","DOI":"10.1073\/pnas.91.9.4082","article-title":"Thalidomide is an inhibitor of angiogenesis","volume":"91","author":"D\u2019Amato","year":"1994","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ijrobp.2010.10.067_bib16","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1006\/exer.1997.0292","article-title":"Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization","volume":"64","author":"Kenyon","year":"1997","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.ijrobp.2010.10.067_bib17","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1056\/NEJM199911183412102","article-title":"Antitumor activity of thalidomide in refractory multiple myeloma","volume":"341","author":"Singhal","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2010.10.067_bib18","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1200\/JCO.2000.18.13.2593","article-title":"Activity of thalidomide in AIDS-related Kaposi\u2019s sarcoma","volume":"18","author":"Little","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2010.10.067_bib19","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1159\/000074477","article-title":"Low-dose thalidomide treatment for advanced hepatocellular carcinoma","volume":"65","author":"Hsu","year":"2003","journal-title":"Oncology"},{"key":"10.1016\/j.ijrobp.2010.10.067_bib20","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/nm0195-27","article-title":"Angiogenesis in cancer, vascular, rheumatoid and other disease","volume":"1","author":"Folkman","year":"1995","journal-title":"Nat Med"},{"key":"10.1016\/j.ijrobp.2010.10.067_bib21","first-page":"3374","article-title":"Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation","volume":"59","author":"Gorski","year":"1999","journal-title":"Cancer Res"},{"key":"10.1016\/j.ijrobp.2010.10.067_bib22","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/28412","article-title":"Combined effects of angiostatin and ionizing radiation in antitumour therapy","volume":"394","author":"Mauceri","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.ijrobp.2010.10.067_bib23","first-page":"1084","article-title":"Cooperative effect of radioimmunotherapy and antiangiogenic therapy with thalidomide in human cancer xenografts","volume":"43","author":"Kinuya","year":"2002","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ijrobp.2010.10.067_bib24","first-page":"1163","article-title":"Antiangiogenic agent, thalidomide increases the antitumor effect of single high dose irradiation (gamma knife radiosurgery) in the rat orthotopic glioma model","volume":"15","author":"Lee","year":"2006","journal-title":"Oncol Rep"},{"key":"10.1016\/j.ijrobp.2010.10.067_bib25","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ijrobp.2007.09.016","article-title":"A phase III study of conventional radiation therapy plus thalidomide versus conventional radiation therapy for multiple brain metastases (RTOG 0118)","volume":"71","author":"Knisely","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2010.10.067_bib26","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.ijrobp.2004.04.023","article-title":"Phase II study of temozolomide and thalidomide with radiation therapy for newly diagnosed glioblastoma multiforme","volume":"60","author":"Chang","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2010.10.067_bib27","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/j.1600-0676.1986.tb00279.x","article-title":"Alpha-fetoprotein changes in the course of chronic hepatitis: Relation to bridging hepatic necrosis and hepatocellular carcinoma","volume":"6","author":"Liaw","year":"1986","journal-title":"Liver"},{"key":"10.1016\/j.ijrobp.2010.10.067_bib28","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/hep.1840060432","article-title":"Early recognition of hepatocellular carcinoma","volume":"6","author":"Okuda","year":"1986","journal-title":"Hepatology"},{"key":"10.1016\/j.ijrobp.2010.10.067_bib29","series-title":"Manual for Staging of Cancer","year":"2009"},{"key":"10.1016\/j.ijrobp.2010.10.067_bib30","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1002\/bjs.1800600817","article-title":"Transection of the oesophagus for bleeding oesophageal varices","volume":"60","author":"Pugh","year":"1973","journal-title":"Br J Surg"},{"key":"10.1016\/j.ijrobp.2010.10.067_bib31","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1007\/s00280-006-0203-z","article-title":"Phase I and pharmacokinetic study of oral thalidomide in patients with advanced hepatocellular carcinoma","volume":"58","author":"Shiah","year":"2006","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ijrobp.2010.10.067_bib32","unstructured":"Cancer Therapy Evaluation Program. Common toxicity criteria, version 3.0. Accessed August 9, 2006. Available from: National Cancer Institute:http:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm#ctc_30."},{"key":"10.1016\/j.ijrobp.2010.10.067_bib33","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6","article-title":"Reporting results of cancer treatment","volume":"47","author":"Miller","year":"1981","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2010.10.067_bib34","doi-asserted-by":"crossref","first-page":"6955","DOI":"10.3748\/wjg.v12.i43.6955","article-title":"Efficacy and safety of thalidomide in patients with hepatocellular carcinoma","volume":"12","author":"Chiou","year":"2006","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.ijrobp.2010.10.067_bib35","doi-asserted-by":"crossref","first-page":"43352","DOI":"10.1074\/jbc.M405777200","article-title":"p38 MAPK mediates gamma-irradiation-induced endothelial cell apoptosis, and vascular endothelial growth factor protects endothelial cells through the phosphoinositide 3-kinase-Akt-Bcl-2 pathway","volume":"279","author":"Kumar","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ijrobp.2010.10.067_bib36","first-page":"1702","article-title":"Simultaneous inhibition of the receptor kinase activity of vascular endothelial, fibroblast, and platelet-derived growth factors suppresses tumor growth and enhances tumor radiation response","volume":"62","author":"Griffin","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.ijrobp.2010.10.067_bib37","first-page":"5565","article-title":"Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions","volume":"60","author":"Lee","year":"2000","journal-title":"Cancer Res"},{"key":"10.1016\/j.ijrobp.2010.10.067_bib38","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/nm0696-689","article-title":"Angiostatin induces and sustains dormancy of human primary tumors in mice","volume":"2","author":"O\u2019Reilly","year":"1996","journal-title":"Nat Med"},{"key":"10.1016\/j.ijrobp.2010.10.067_bib39","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1126\/science.1062892","article-title":"Cancer: What does radiotherapy do to endothelial cells?","volume":"293","author":"Folkman","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.ijrobp.2010.10.067_bib40","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1158\/1078-0432.743.11.2","article-title":"Thalidomide radiosensitizes tumors through early changes in the tumor microenvironment","volume":"11","author":"Ansiaux","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2010.10.067_bib41","doi-asserted-by":"crossref","first-page":"7911","DOI":"10.1158\/0008-5472.CAN-05-1288","article-title":"Tumor radiosensitization by antiinflammatory drugs: Evidence for a new mechanism involving the oxygen effect","volume":"65","author":"Crokart","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.ijrobp.2010.10.067_bib42","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.1200\/JCO.2008.20.9908","article-title":"Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: A phase II study","volume":"27","author":"Zhu","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2010.10.067_bib43","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1158\/1541-7786.MCR-06-0103","article-title":"Stromal cell-derived factor-1\/chemokine (C-X-C motif) ligand 12 stimulates human hepatoma cell growth, migration, and invasion","volume":"5","author":"Sutton","year":"2007","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.ijrobp.2010.10.067_bib44","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1093\/annonc\/mdm448","article-title":"Circulating interleukin-6 as a tumor marker for hepatocellular carcinoma","volume":"19","author":"Porta","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijrobp.2010.10.067_bib45","doi-asserted-by":"crossref","first-page":"2992","DOI":"10.1200\/JCO.2007.15.9947","article-title":"Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma","volume":"26","author":"Siegel","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2010.10.067_bib46","doi-asserted-by":"crossref","first-page":"4672","DOI":"10.1200\/JCO.2008.16.1612","article-title":"Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100","volume":"26","author":"Schneider","year":"2008","journal-title":"J Clin Oncol"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301610036394?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301610036394?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,6,5]],"date-time":"2023-06-05T00:39:09Z","timestamp":1685925549000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301610036394"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2]]},"references-count":46,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,2]]}},"alternative-id":["S0360301610036394"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2010.10.067","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2012,2]]}}}